We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 22, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
BLISTER TRACK INHALER DEVICE HAVING A SEPARATE END PATH AND METHODS OF USE THEREOF
DRUG DELIVERY SYSTEMS
NOVEL PHARMACEUTICAL COMPOSITION
METHODS OF ADMINISTRATION OF THROMBOPOIETIN AGONIST COMPOUNDS
INTERMITTENT DOSING OF MDM2 INHIBITOR
PHARMACEUTICAL DOSAGE FORMS
PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES
GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER
MDM2 INHIBITORS AND COMBINATIONS THEREOF
COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING